ENDO PHARMACEUTICALS HOLDINGS INC Form 8-K July 22, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): July 22, 2008 (July 16, 2008)

Endo Pharmaceuticals Holdings Inc.

 $(Exact\ name\ of\ registrant\ as\ specified\ in\ its\ charter)$

Delaware (State or other jurisdiction

001-15989 (Commission File Number) 13-4022871 (I.R.S. Company

of incorporation)

Identification No.)

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 8-K


100 Endo Boulevard, Chadds Ford, PA (Address of principal executive offices)

19317 (Zip Code)

Registrant s telephone number, including area code (610) 558-9800

Not Applicable

Former name or former address, if changed since last report



- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 8-K

Item 1.01 Entry into a Material Definitive Agreement.

On July 16, 2008, the Registrant s wholly owned subsidiary, Endo Pharmaceuticals Inc. (Endo) and Penwest Pharmaceuticals Co. (Penwest) entered into a second amendment, referred to as the Second Amendment, to the 2002 Amended and Restated Strategic Alliance Agreement between the parties (the 2002 Agreement). Under the terms of the Second Amendment, Endo and Penwest agreed to restructure the 2002 Agreement to change the manner in which Endo reimburses Penwest for costs and fees incurred by Penwest in connection with patent enforcement litigation.

The foregoing description of the Second Amendment does not purport to be complete and is qualified in its entirety to the full text of the Second Amendment, a copy of which will be filed with the exhibits to the Company s quarterly report on Form 10-Q for the period ended June 30, 2008.

Item 9.01. Financial Statements and Exhibits.

- (a) Financial Statements of Business Acquired. Not applicable.
- (b) *Pro Forma Financial Information*. Not applicable.
- (c) Shell Company Transactions Not applicable.
- (d) *Exhibits*. Not applicable.

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ENDO PHARMACEUTICALS HOLDINGS INC. (Registrant)

By: /s/ Caroline B. Manogue Name: Caroline B. Manogue

Title: Executive Vice President, Chief Legal Officer &

Secretary

Dated: July 22, 2008